Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a24aa1ee4b32e88e

Jump to content

// Workers AI · dad joke modeWhat did Lateral Pharma say to the pill? "You're always side-affected by me.

Add links
From Wikipedia, the free encyclopedia
Lateral Pharma Pty Ltd
TypePrivate
IndustryBiotechnology
FoundedMay 2015
HeadquartersMelbourne, Victoria, Australia
Key people
David Kenley (CEO)
Andy Gearing (CSO)
Stuart Mudge (COO)
David Williamson (CFO)
Websitelateral-pharma.com

Lateral Pharma is a biotechnology company based in Melbourne, Australia focused on developing therapeutics for treatment of neuropathic pain, and neurodegeneration. The company has discovered a range of Stressed Cell Protectant drugs (SCPs) targeting the LanC-like (LanCL) protein family to address these indications.[1][2]

History

[edit]

Lateral Pharma was established in May 2015 to repurpose LAT8881, a 16 amino acid C-terminal fragment of hGH, that was previously investigated for the treatment of obesity. It was found to have a good safety profile but ceased development due to failure to show efficacy after oral delivery.[3][4]

Lateral discovered that LAT8881 was active in rodent models of neuropathy caused by nerve injury, chemotherapy and diabetes, and of pneumonia caused by Influenza A, SARS-CoV-2 and Streptococcus pneumoniae.[5][6] In 2023, Lateral Pharma completed a human Phase 1b clinical trial demonstrating proof-of-concept for intravenous LAT8881 in treating chronic lumbar radicular pain (sciatica), a common condition that is poorly treated.[7][8]

Whilst conducting SAR research around LAT8881, Lateral Pharma discovered a portfolio of similar active peptides (SCPs) derived from a total of five mammalian proteins/hormones, including its current lead compound LAT9997, a 6 amino acid fragment of LAT8881 that is suitable for sub-cutaneous administration.[9][10]

In February 2026, Lateral's work on extending Healthspan was recognized with a silver medal in the Start-up pitch competition at the National University of Singapore Healthy Longevity Conference.[11]

Products and services

[edit]

LAT9997, which was granted a US patent in December 2025, and Lateral's other SCPs target the LanCL protein family host-protective biological pathway to restore normal cellular function in stressed tissues.[12][13] LAT9997, a highly soluble linear 6-amino acid peptide, is being investigated for the treatment of sciatica, neuropathic pain, neurodegenerative disorders, pneumonia and other conditions that impact healthy longevity.[14][15][16]

LanCL proteins have been implicated in the pathology of multiple diseases of the nervous system, lung, heart and metabolic systems.[17][18][19][20]

LAT9997 has shown efficacy in rodent models of pneumonia, neuropathy, and Alzheimer's disease.[9][21]

Operations

[edit]

The company operates from Melbourne and focuses on research and clinical development of drugs that target the LanCL biological pathway. Lateral Pharma runs a semi-virtual operation and collaborates with institutions including the Hudson Institute of Medical Research in Melbourne, Australia and contract research organizations including Evotec.[22] It has conducted human trials in Australia and the United Kingdom. Lateral Pharma has received grant support from the Victorian Medical Research Acceleration Fund in 2023 and Australian government programs for innovation and growth services.[23][24]

References

[edit]
  1. ↑ Masfiah, S. (2025). "Definitions of healthspan: A systematic review". Ageing Research Reviews. 111 102806. doi:10.1016/j.arr.2025.102806. PMID 40523529. Retrieved 13 May 2026.
  2. ↑ Pachacz, Mark (11 September 2025). "Lateral Pharma - A First-in Class Pain Therapeutic with a Novel target and a Fascinating History" (PDF). Bioshares (980 ed.). Blake Industry & Market Analysis Pty Ltd. ISSN 1443-850X. Retrieved 13 May 2026.
  3. ↑ Moré, Margret I.; Kenley, David (June 2014). "Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health". Journal of Endocrinology and Metabolism. 4 (3): 64–77. doi:10.14740/jem213w. Retrieved 13 May 2026.
  4. ↑ "PROOF-OF-CONCEPT CLINICAL TRIAL SUCCESSFULLY COMPLETED WITH LAT8881". BioMelbourne Network. 17 October 2023. Retrieved 13 May 2026.
  5. ↑ Spanswick, David; Wei, Haifeng; Zhao, Fei-Yue; Caldeira Borges da Cruz, Matilde; Whyment, Andrew; Campbell-Galland, Adam; Pickering, Anthony E.; Imlach, Wendy (16 March 2026). "Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain". Pain. Retrieved 13 May 2026.
  6. ↑ Zhang, J. (2025). "LANCL1 as a therapeutic target for diabetes and obesity". Clinical & Translational Immunology. 14 (3) e1443. doi:10.1002/cti2.1443. PMC 10034483. PMID 36969366.
  7. ↑ "A Two-part Proof-of-Concept Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous LAT8881 in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus". ClinicalTrials.gov. National Library of Medicine (U.S.). 20 March 2022. NCT05298306. Retrieved 13 May 2026.
  8. ↑ "EudraCT Number 2018-004534-15 - Clinical trial results". EU Clinical Trials Register. Retrieved 13 May 2026.
  9. 1 2 West, Alison C. (April 2026). "Short-course intranasal LAT9997 therapy limits post-influenza bacterial pneumonia by recalibrating lung immunity". Mucosal Immunology. 19 (2): 1875–1888. doi:10.1016/j.mucimm.2026.01.008. PMID 41581760. Retrieved 13 May 2026.
  10. ↑ "Controlling inflammation to conquer lung infection". Hudson Institute of Medical Research. 16 January 2024. Retrieved 13 May 2026.
  11. ↑ "Lateral Pharma Awarded Second Place at International Pitch Competition". Lateral Pharma. 1 March 2026. Retrieved 13 May 2026.
  12. ↑ "Lateral Pharma secures key US patent for novel neuropathic pain therapy". Biotech Dispatch. 10 March 2026. Retrieved 13 May 2026.
  13. ↑ McDonald, Emily K.; Paolini, Antonio G. (16 August 2024). "Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza". The Journal of Infectious Diseases. 230 (2): e384–e394. doi:10.1093/infdis/jiad566. PMC 11326819. PMID 38060822.
  14. ↑ "LAT 8881 - Lateral Pharma". AdisInsight. Springer. Retrieved 13 May 2026.
  15. ↑ Mudge, Stuart (7 August 2024). "Putative Plasma PD Biomarkers Identified from Clinical Study of LAT8881 in Lumbar Radicular Pain". IASP WorldCongress 2024. Retrieved 13 May 2026.
  16. ↑ Paolini, Antonio G. (23 March 2023). "Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection". Clinical & Translational Immunology. 12 (3) e1443. doi:10.1002/cti2.1443. PMC 10034483. PMID 36969362.
  17. ↑ Cui, Z. (19 April 2025). "Discovering genetically-supported drug targets for multisite chronic pain through multi-omics Mendelian randomization and single-cell RNA-sequencing". Neuroscience. 572: 254–268. doi:10.1016/j.neuroscience.2025.02.038. PMID 39993665. Retrieved 13 May 2026.
  18. ↑ Tan, Honglin (29 September 2020). "LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice". Acta Neuropathologica Communications. 8 (1): 1369–1382. doi:10.1038/s41418-019-0422-6. PMC 7206132. PMID 31570855.
  19. ↑ Kogan, V. (2018). "Genetic-Epigenetic Interactions in Asthma Revealed by a Genome-Wide Gene-Centric Search". Human Heredity. 83 (3): 130–152. doi:10.1159/000489765. PMC 7365350. PMID 30669148.
  20. ↑ He, Wei; Tang, Panli (2025). "The role of senescence-related hub genes correlating with immune infiltration in type a aortic dissection: Novel insights based on bioinformatic analysis". PLOS ONE. 20 (6) e0326939. Bibcode:2025PLoSO..2026939H. doi:10.1371/journal.pone.0326939. PMC 12194205. PMID 40561071.
  21. ↑ "Study Details NCT03865953 Oral LAT8881 in Neuropathic Pain". ClinicalTrials.gov. 20 May 2021. Retrieved 13 May 2026.
  22. ↑ Bechwati, Jennifer (9 April 2026). "Melbourne scientists develop breakthrough flu puffer to prevent deadly pneumonia". 7NEWS. Retrieved 13 May 2026.
  23. ↑ "Lateral Pharma Awarded Support via Victorian Medical Research Acceleration Fund". Lateral Pharma. 9 May 2023. Retrieved 13 May 2026.
  24. ↑ "Lateral Pharma Awarded Innovations Connections Grant". Lateral Pharma. 6 August 2021. Retrieved 13 May 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lateral_Pharma&oldid=1364261742"